{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:36:23Z","timestamp":1768638983794,"version":"3.49.0"},"reference-count":57,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI19\/00254"],"award-info":[{"award-number":["FI19\/00254"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI1800943"],"award-info":[{"award-number":["PI1800943"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3 Dr. Ferran","award":["2017"],"award-info":[{"award-number":["2017"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,11,27]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Fibromyalgia syndrome (FMS) imposes a high cost on society. The significant economic burden from the use of healthcare and, especially, social resources is a spur to revising the usual clinical care (UCC) and to improving treatment strategies. FMS has a deleterious effect on the quality of life (QOL) and productivity, which considerably increase the indirect costs to society. This study reports an economic evaluation comparing the cost and health benefits in a multicomponent intervention programme and UCC of patients with FMS who attend primary healthcare centres of the Ger\u00e8ncia Territorial Terres de L\u2019Ebre region of Catalonia, Spain. This article is linked to the pre-results of a randomised control trial study on the implementation of this intervention programme (ClinicalTrials.gov:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04049006\">NCT04049006<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method and analysis<\/jats:title>\n                    <jats:p>A cost\u2013utility analysis will be conducted from a societal perspective. Quality-adjusted life years will be calculated from the results of the SF-36 questionnaire, a QOL measurement instrument. Direct and indirect healthcare costs will be obtained from official prices and reports published by the Spanish Public Health Administration and the National Statistics Institute. The incremental cost\u2013utility ratio will be estimated to compare the two healthcare practices. Deterministic sensitivity analysis will also be used to compare different cost scenarios, modifying the items with the highest weight in the cost composition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The Clinical Research Ethics Committee of the IDIAPJGol Institute approved this study on 25 April 2018 (code P18\/068) in accordance with the Helsinki\/Tokyo Declaration. Information will be provided orally and in writing to participants, and their informed consent will be required. Participant anonymity will be guaranteed. The dissemination strategy includes publications in scientific journals and presentations in local and national media and at academic conferences.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial registration number:<\/jats:bold>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04049006\">NCT04049006<\/jats:ext-link>\n                      ; Pre-results.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-043562","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T15:18:25Z","timestamp":1612711105000},"page":"e043562","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Cost\u2013utility analysis of a multicomponent intervention for fibromyalgia syndrome in primary care versus usual clinical practice: study protocol for an economic evaluation of a randomised control trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04049006","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04049006","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04049006","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-6907","authenticated-orcid":false,"given":"Victoria Mailen","family":"Arfuch","sequence":"first","affiliation":[{"name":"Unitat de Suport a la Recerca Terres de l\u2019Ebre, IDIAP Jordi Gol, Barcelona, Catalunya, Spain"},{"name":"Department of Pediatrics, Obstetrics and Gynecology, and Preventive Medicine, Universitat Autonoma de Barcelona, Barcelona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Aguilar Mart\u00edn","sequence":"additional","affiliation":[{"name":"Unitat de Suport a la Recerca Terres de l\u2019Ebre, IDIAP Jordi Gol, Barcelona, Catalunya, Spain"},{"name":"Unitat d\u2019Avaluaci\u00f3, Direcci\u00f3 d\u2019Atenci\u00f3 Prim\u00e0ria Terres de l\u2019Ebre, Institut Catal\u00e0 de la Salut, Tortosa, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0889-2002","authenticated-orcid":false,"given":"Anna","family":"Berenguera","sequence":"additional","affiliation":[{"name":"Central Research Unit, IDIAP Jordi Gol, Barcelona, Catalunya, Spain"},{"name":"Department of Pediatrics, Obstetrics and Gynecology, and Preventive Medicine, Universitat Autonoma de Barcelona, Barcelona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Caballol Angelats","sequence":"additional","affiliation":[{"name":"Equip d\u2019Atenci\u00f3 Prim\u00e0ria Tortosa Est, Institut Catal\u00e0 de la Salut, Tortosa, Catalonia, Spain"},{"name":"Unitat d\u2019Expertesa en Sindromes de Sensibilitzaci\u00f3 Central Terres de l\u2019Ebre, Institut Catal\u00e0 de la Salut, Tortosa, Catalonia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e8lia","family":"Carrasco-Querol","sequence":"additional","affiliation":[{"name":"Unitat de Suport a la Recerca Terres de l\u2019Ebre, IDIAP Jordi Gol, Barcelona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Gonz\u00e1lez Serra","sequence":"additional","affiliation":[{"name":"Unitat de Suport a la Recerca Terres de l\u2019Ebre, IDIAP Jordi Gol, Barcelona, Catalunya, Spain"},{"name":"Unitat d\u2019Expertesa en Sindromes de Sensibilitzaci\u00f3 Central Terres de l\u2019Ebre, Institut Catal\u00e0 de la Salut, Tortosa, Catalonia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cinta","family":"Sancho Sol","sequence":"additional","affiliation":[{"name":"Unitat de Suport a la Recerca Terres de l\u2019Ebre, IDIAP Jordi Gol, Barcelona, Catalunya, Spain"},{"name":"Unitat d\u2019Expertesa en Sindromes de Sensibilitzaci\u00f3 Central Terres de l\u2019Ebre, Institut Catal\u00e0 de la Salut, Tortosa, Catalonia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immaculada","family":"Fust\u00e9 Anguera","sequence":"additional","affiliation":[{"name":"Equip d\u2019Atenci\u00f3 Prim\u00e0ria Tortosa Est, Institut Catal\u00e0 de la Salut, Tortosa, Catalonia, Spain"},{"name":"Unitat d\u2019Expertesa en Sindromes de Sensibilitzaci\u00f3 Central Terres de l\u2019Ebre, Institut Catal\u00e0 de la Salut, Tortosa, Catalonia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Fern\u00e1ndez S\u00e1ez","sequence":"additional","affiliation":[{"name":"Unitat de Suport a la Recerca Terres de l\u2019Ebre, IDIAP Jordi Gol, Barcelona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra Queiroga","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Unitat de Suport a la Recerca Terres de l\u2019Ebre, IDIAP Jordi Gol, Barcelona, Catalunya, Spain"},{"name":"Unitat Docent de Medicina de Fam\u00edlia i Comunit\u00e0ria Tortosa-Terres de L\u2018Ebre, Institut Catal\u00e0 de la Salut, Tortosa, Catalonia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Casajuana","sequence":"additional","affiliation":[{"name":"Central Research Unit, IDIAP Jordi Gol, Barcelona, Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"2025120519530800000_11.2.e043562.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"2025120519530800000_11.2.e043562.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100594"},{"key":"2025120519530800000_11.2.e043562.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"2025120519530800000_11.2.e043562.4","first-page":"358","article-title":"Fibromyalgia: clinical and occupational aspects","volume":"58","author":"Helfenstein","year":"2012","journal-title":"Rev Assoc Med Bras"},{"key":"2025120519530800000_11.2.e043562.5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40273-014-0137-y","article-title":"Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden","volume":"32","author":"Skaer","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"2025120519530800000_11.2.e043562.6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.rbr.2016.10.004","article-title":"Prevalence of fibromyalgia: literature review update","volume":"57","author":"Marques","year":"2017","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"2025120519530800000_11.2.e043562.7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.reuma.2017.06.009","article-title":"Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): aims and methodology","volume":"15","author":"Seoane-Mato","year":"2019","journal-title":"Reumatol Clin"},{"key":"2025120519530800000_11.2.e043562.8","first-page":"1318","article-title":"Economic cost and epidemiological characteristics of patients with fibromyalgia claims","volume":"30","author":"Robinson","year":"2003","journal-title":"J Rheumatol"},{"key":"2025120519530800000_11.2.e043562.9","first-page":"2","article-title":"Costs, and the economic burden of fibromyalgia","volume":"11","author":"Epidemiology","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2025120519530800000_11.2.e043562.10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2673","article-title":"Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study","volume":"11","author":"Sicras-Mainar","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2025120519530800000_11.2.e043562.11","first-page":"S39","article-title":"Resource utilisation and health care costs in patients diagnosed with fibromyalgia in Spain","volume":"27","author":"Rivera","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2025120519530800000_11.2.e043562.12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PHM.0b013e3181fc7ff3","article-title":"Direct medical costs in patients with fibromyalgia: cost of illness and impact of a brief multidisciplinary treatment program","volume":"90","author":"Thompson","year":"2011","journal-title":"Am J Phys Med Rehabil"},{"key":"2025120519530800000_11.2.e043562.13","first-page":"S74","article-title":"Cost of illness and illness perceptions in patients with fibromyalgia","volume":"34","author":"Vervoort","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025120519530800000_11.2.e043562.14","first-page":"885","article-title":"The London fibromyalgia epidemiology study: direct health care costs of fibromyalgia syndrome in London, Canada","volume":"26","author":"White","year":"1999","journal-title":"J Rheumatol"},{"key":"2025120519530800000_11.2.e043562.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01480.x"},{"key":"2025120519530800000_11.2.e043562.16","first-page":"S126","article-title":"Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia","volume":"16","author":"Berger","year":"2010","journal-title":"Am J Manag Care"},{"key":"2025120519530800000_11.2.e043562.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019711"},{"key":"2025120519530800000_11.2.e043562.18","doi-asserted-by":"publisher","DOI":"10.2165\/11535250-000000000-00000"},{"key":"2025120519530800000_11.2.e043562.19","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-016-1143-8"},{"key":"2025120519530800000_11.2.e043562.20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.medcli.2017.06.008","article-title":"Fibromyalgia: prevalence, epidemiologic profiles and economic costs","volume":"149","author":"Cabo-Meseguer","year":"2017","journal-title":"Med Clin"},{"key":"2025120519530800000_11.2.e043562.21","unstructured":"Instituto Nacional de la Seguridad social. Guia de actualizaci\u00f3n en La valoraci\u00f3n de fibromialgia, s\u00cdndrome de fatiga cr\u00f3nica, sensibilidad qu\u00edmica m\u00faltiple Y electrosensibilidad. Segunda Edici\u00f3n 2019 https:\/\/www.semg.es\/images\/documentos\/guia_fibromialgia_2019.pdf"},{"key":"2025120519530800000_11.2.e043562.22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3111\/13696990701605235","article-title":"Economic evaluation in health: saving money or improving care?","volume":"10","author":"Chisholm","year":"2007","journal-title":"J Med Econ"},{"key":"2025120519530800000_11.2.e043562.23","doi-asserted-by":"crossref","unstructured":"Franklin M . Cost utility analysis. in: mental health economics: the costs and benefits of psychiatric care. Cham. Springer International Publishing 2017:89\u2013119.","DOI":"10.1007\/978-3-319-55266-8_6"},{"key":"2025120519530800000_11.2.e043562.24","unstructured":"Mccabe C . What is cost-utility analysis? Hayward Med Commun 2009:1\u20136 http:\/\/www.bandolier.org.uk\/painres\/download\/whatis\/What_is_cost-util.pdf"},{"key":"2025120519530800000_11.2.e043562.25","first-page":"1246","article-title":"Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. II. economic evaluation","volume":"23","author":"Goossens","year":"1996","journal-title":"J Rheumatol"},{"key":"2025120519530800000_11.2.e043562.26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/AJP.0b013e318270f99a","article-title":"Cost-Utility of a psychoeducational intervention in fibromyalgia patients compared with usual care: an economic evaluation alongside a 12-month randomized controlled trial","volume":"29","author":"Luciano","year":"2013","journal-title":"Clin J Pain"},{"key":"2025120519530800000_11.2.e043562.27","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0482-4"},{"key":"2025120519530800000_11.2.e043562.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2017.03.001"},{"key":"2025120519530800000_11.2.e043562.29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jpain.2018.07.012","article-title":"Cost-Effectiveness and cost-utility of internet-delivered exposure therapy for fibromyalgia: results from a randomized, controlled trial","volume":"20","author":"Hedman-Lagerl\u00f6f","year":"2019","journal-title":"J Pain"},{"key":"2025120519530800000_11.2.e043562.30","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/jcm8071068","article-title":"Cost\u2013Utility of Mindfulness-Based stress reduction for fibromyalgia versus a multicomponent intervention and usual care: a 12-month randomized controlled trial (EUDAIMON study)","volume":"8","author":"P\u00e9rez-Aranda","year":"2019","journal-title":"JCM"},{"key":"2025120519530800000_11.2.e043562.31","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030726","article-title":"Cost-Utility of Attachment-Based compassion therapy (ABCT) for fibromyalgia compared to relaxation: a pilot randomized controlled trial","volume":"9","author":"D\"Amico","year":"2020","journal-title":"J Clin Med"},{"key":"2025120519530800000_11.2.e043562.32","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31820b131c"},{"key":"2025120519530800000_11.2.e043562.33","unstructured":"Celaya M , Ib\u00e1\u00f1ez D , Laseca N . Guia per a l\"avaluaci\u00f3 de la fibromi lgia i de la s\u00edndrome de fatiga cr\u00f2nica. Generalitat de Catalunya, 2017. Available: https:\/\/canalsalut.gencat.cat\/web\/.content\/_A-Z\/F\/fibromialgia\/documents\/guia_avaluacio_fibromialgia_fatiga_cronica.pdf [Accessed 20 Feb 2020]."},{"key":"2025120519530800000_11.2.e043562.34","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017289","article-title":"Effectiveness, cost-utility, and benefits of a multicomponent therapy to improve the quality of life of patients with fibromyalgia in primary care","volume":"98","author":"Caballol Angelats","year":"2019","journal-title":"Medicine"},{"key":"2025120519530800000_11.2.e043562.35","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017289","article-title":"Effectiveness, cost-utility, and benefits of a multicomponent therapy to improve the quality of life of patients with fibromyalgia in primary care: a mixed methods study protocol","volume":"98","author":"Caballol Angelats","year":"2019","journal-title":"Medicine"},{"key":"2025120519530800000_11.2.e043562.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.02.002"},{"key":"2025120519530800000_11.2.e043562.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2012.09.010"},{"key":"2025120519530800000_11.2.e043562.38","unstructured":"Nishishinya Aquino B , Requeijo Lorenzo C , Roqu\u00e9 F\u00edguls M . Evaluaci\u00f3n Y abordaje de la fibromialgia. Actualizaci\u00f3n de las evidencias cient\u00edficas. Barcelona. Ministerio de Sanidad, Servicios Sociales e Igualdad. Ag\u00e8ncia de Qualitat i Avaluaci\u00f3 Sanit ries de Catalunya. Departament de Salut. Generalitat de Catalunya 2017. (Informes de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias) https:\/\/aquas.gencat.cat\/web\/.content\/minisite\/aquas\/publicacions\/2017\/Fibromialgia_actualizacion_RedETS2017.pdf"},{"key":"2025120519530800000_11.2.e043562.39","unstructured":"G\u00e1ndara M , Mu\u00f1oz G . Evaluaci\u00f3n Y abordaje de la fibromialgia Y El s\u00edndrome de fatiga cr\u00f3nica. D\u00eda Mundial de la Fibromialgia Y El S\u00edndrome de Fatiga Cr\u00f3nica. Oficial Nacional de Salud P\u00fablica-AEMPPI Ecuador 2017 https:\/\/www.elsevier.com\/es-es\/connect\/actualidad-sanitaria\/dia-mundial-de-la-fibromialgia-y-el-sindrome-de-fatiga-cronica?aaref=https%3A%2F%2Fwww.google.com%2F"},{"key":"2025120519530800000_11.2.e043562.40","unstructured":"Alonso J et al . Versi\u00f3n espa\u00f1ola de SF-36v2TM health survey \u00a9 1996, 2000, adapted by J. Alonso, et al. Heal Surv 2003:1\u20138 http:\/\/www.ser.es\/wp-content\/uploads\/2015\/03\/SF36_CUESTIONARIOpdf.pdf"},{"key":"2025120519530800000_11.2.e043562.41","unstructured":"Catalunya Gde . Diari Oficial de la Generalitat de Catalunya. Available: https:\/\/dogc.gencat.cat\/es"},{"key":"2025120519530800000_11.2.e043562.42","unstructured":"Espa\u00f1a Gde . Real Decreto 8\/2015 POR El que Se aprueba El texto refundido de la Ley General de la Seguridad social. Bolet\u00edn Oficial del Estado 2015:1\u2013157 http:\/\/www.boe.es\/boe\/dias\/1994\/06\/29\/pdfs\/A20658-20708.pdf"},{"key":"2025120519530800000_11.2.e043562.43","unstructured":"Estad\u00edstica INde . (ine). Coste laboral POR trabajador, comunidad aut\u00f3noma, sectores de actividad. Available: https:\/\/www.ine.es\/jaxiT3\/Tabla.htm?t=6061 [Accessed 20 Mar 2020]."},{"key":"2025120519530800000_11.2.e043562.44","doi-asserted-by":"crossref","unstructured":"Andronis L , Barton P , Bryan S . Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technol Assess 2009;13.doi:10.3310\/hta13290","DOI":"10.3310\/hta13290"},{"key":"2025120519530800000_11.2.e043562.45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1586\/14737175.2015.1046841","article-title":"Fibromyalgia diagnosis: a review of the past, present and future","volume":"15","author":"Wang","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"2025120519530800000_11.2.e043562.46","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2017.1275191","article-title":"The social construction of fibromyalgia as a health problem from the perspective of policies, professionals, and patients","volume":"10","author":"Briones-Vozmediano","year":"2017","journal-title":"Glob Health Action"},{"key":"2025120519530800000_11.2.e043562.47","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/BOR.0000000000000464","article-title":"The complexities of fibromyalgia and its comorbidities","volume":"30","author":"Lichtenstein","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2025120519530800000_11.2.e043562.48","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7375468"},{"key":"2025120519530800000_11.2.e043562.49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126324","article-title":"Multicomponent interdisciplinary group intervention for self-management of fibromyalgia: a mixed-methods randomized controlled trial","volume":"10","author":"Bourgault","year":"2015","journal-title":"PLoS One"},{"key":"2025120519530800000_11.2.e043562.50","first-page":"1","article-title":"A 12-week multicomponent therapy in fibromyalgia improves health but not in concomitant moderate depression, an exploratory pilot study","volume":"0","author":"Ollevier","year":"2019","journal-title":"Disabil Rehabil"},{"key":"2025120519530800000_11.2.e043562.51","first-page":"103","article-title":"Six-and 12-month follow-up of an interdisciplinary fibromyalgia treatment programme: results of a randomised trial","volume":"30","author":"Mart\u00edn","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2025120519530800000_11.2.e043562.52","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00296-016-3473-8","article-title":"The effects of long- and short-term interdisciplinary treatment approaches in women with fibromyalgia: a randomized controlled trial","volume":"36","author":"Saral","year":"2016","journal-title":"Rheumatol Int"},{"key":"2025120519530800000_11.2.e043562.53","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.sjpain.2013.06.003","article-title":"Effectiveness of multidisciplinary rehabilitation treatment for patients with chronic pain in a primary health care unit","volume":"4","author":"Stein","year":"2013","journal-title":"Scand J Pain"},{"key":"2025120519530800000_11.2.e043562.54","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.06.008","article-title":"Economic evaluation in implementation science: making the business case for implementation strategies","volume":"283","author":"Eisman","year":"2020","journal-title":"Psychiatry Res"},{"key":"2025120519530800000_11.2.e043562.55","unstructured":"Anneliese P , Hoch J . Understanding cost-utility analysis in health care. Univ Toronto Med J 2006;83(2 http:\/\/utmj.org\/index.php\/UTMJ\/article\/view\/734"},{"key":"2025120519530800000_11.2.e043562.56","first-page":"433","article-title":"Cost-Utility analysis: use QALYs only with great caution","volume":"168","author":"McGregor","year":"2003","journal-title":"CMAJ"},{"key":"2025120519530800000_11.2.e043562.57","unstructured":"Tarter T , Johnson G , Johnson R . Neuropsychology of Cancer and Oncology.. In: Noggle CA , Dean RS , eds. New York: Springer Publishing Company, 2013: 3\u20135."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-043562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:53:21Z","timestamp":1764993201000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-043562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,5]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bmjopen-2020-043562"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-043562","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}